Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 28;26(3):106290.
doi: 10.1016/j.isci.2023.106290. eCollection 2023 Mar 17.

Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT

Jinhua Ren  1 , QiaoXian Lin  2 , Qi Chen  3 , Jingjing Xu  1 , Dabin Chen  1 , Renli Chen  3 , Kangni Lin  4 , Haojie Zhu  1 , Chenjing Ye  1 , Xiaofeng Luo  1 , Shaozhen Chen  1 , Hui Kong  1 , Qiong Lin  1 , Nan Li  1 , Xu Lin  5 , Zhizhe Chen  1 , Jianda Hu  1 , Ting Yang  1
Affiliations

Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT

Jinhua Ren et al. iScience. .

Abstract

Adoptive transfer of hepatitis B virus (HBV) immunity may occur following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we investigated the adoptive transfer of HBV immunity in 112 patients without HBV surface antibody (HBsAb) (HBsAb-) at the time of their first allo-HSCT. After allo-HSCT, HBV-DNA（87.5%） and HBsAg（11.1%%）cleared in HBsAg+ patients. All HBsAg- patients acquired HBsAb immediately. Nevertheless, HBsAb titers subsequently declined, and 39/67 (58.2%) patients lost HBsAb during follow-up. The 5-year overall survival (OS) was better in patients who lost HBsAb. Multivariate analysis showed that the independent risk factors for OS were lack of cytomegalovirus (CMV) clearance, acute graft-versus-host disease (aGVHD), and no HBsAb loss. Overall, adoptive immune transfer offers anti-HBV protection to patients without HBsAb, as they acquire HBsAb and clear HBV-DNA and HBsAg, while HBsAb loss after allo-HSCT predicts better survival.

Keywords: Immunology; Virology.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

None
Graphical abstract
Figure 1
Figure 1
112 patients without HBsAb who underwent allo-HSCT were enrolled in this study
Figure 2
Figure 2
HBsAb titer changes over time after allo-HSCT (A) HBsAb titer changes in all patients over time after allo-HSCT; (B) HBsAb titer changes after allo-HSCT in patients with donor HbcAb+ and HbcAb-; (C) HBsAb titer changes after allo-HSCT in patients with donor HbsAb≥ 10IU/ml and HbsAb<10IU/ml; (D) HBsAb titer changes after allo-HSCT in patients with HbsAb lost and HbsAb not lost.
Figure 3
Figure 3
Patients survival after allo-HSCT (A) Rate of OS according to HBsAg+ and HBsAg- group before transplantation (p = 0.5152). (B) Rate of OS according to HBsAb loss and HBsAb not loss groups after transplantation (p < 0.0001). (C) Rate of OS according to aGVHD and without aGVHD groups after transplantation (p = 0.0328). (D) Rate of OS according to CMV clearance and CMV unclearance groups after transplantation(p < 0.0001).
Figure 4
Figure 4
Immune reconstitution in HBsAb loss and HBsAb not loss patients (A) IgM level in HBsAb loss and HBsAb not loss groups (p = 0.037). (B) CD3+CD4+ T lymphocytes in HBsAb loss and HBsAb not loss groups (p = 0.005). (C) CD3+CD8+ T lymphocytes in HBsAb loss and HBsAb not loss groups (p = 0.013). (D) Absolute lymphocyte count in HBsAb loss and HBsAb not loss groups (p = 0.008).
See this image and copyright information in PMC

References

    1. Gratwohl A., Baldomero H., Aljurf M., Pasquini M.C., Bouzas L.F., Yoshimi A., Szer J., Lipton J., Schwendener A., Gratwohl M., et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617–1624. doi: 10.1001/jama.2010.491. - DOI - PMC - PubMed
    1. D'Souza A., Lee S., Zhu X., Pasquini M. Current use and trends in hematopoietic cell transplantation in the United States. Biol. Blood Marrow Transplant. 2017;23:1417–1421. doi: 10.1016/j.bbmt.2017.05.035. - DOI - PMC - PubMed
    1. Copelan E.A., Chojecki A., Lazarus H.M., Avalos B.R. Allogeneic hematopoietic cell transplantation; the current renaissance. Blood Rev. 2019;34:34–44. doi: 10.1016/j.blre.2018.11.001. - DOI - PubMed
    1. Mikulska M., Nicolini L., Signori A., Rivoli G., Del Bono V., Raiola A.M., Di Grazia C., Dominietto A., Varaldo R., Ghiso A., et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. Clin. Microbiol. Infect. 2014;20:O694–O701. doi: 10.1111/1469-0691.12611. - DOI - PubMed
    1. Yan C.H., Xu L.P., Wang F.R., Chen H., Han W., Wang Y., Wang J.Z., Liu K.Y., Huang X.J. Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51:391–397. doi: 10.1038/bmt.2015.306. - DOI - PubMed